Cover Image
市場調查報告書

幼年型慢性關節炎:開發中產品分析

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363116
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
幼年型慢性關節炎:開發中產品分析 Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 56 Pages
簡介

本報告提供幼年型慢性關節炎治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

幼年型慢性關節炎概要

治療藥的開發

  • 開發中產品的概要

幼年型慢性關節炎:企業開發中的治療藥

幼年型慢性關節炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

幼年型慢性關節炎:企業開發中的產品

幼年型慢性關節炎治療藥的開發企業

  • Alteogen Inc.
  • Bristol-Myers Squibb Company
  • Epirus Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.

幼年型慢性關節炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

幼年型慢性關節炎:暫停中的計劃

幼年型慢性關節炎:中止開發的產品

幼年型慢性關節炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9691IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 5 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Idiopathic Juvenile Arthritis - Overview
    • Systemic Idiopathic Juvenile Arthritis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
    • Alteogen Inc
    • Johnson & Johnson
    • Livzon Pharmaceutical Group Inc
    • Mycenax Biotech Inc
    • Novartis AG
    • Oncobiologics Inc
  • Systemic Idiopathic Juvenile Arthritis - Drug Profiles
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • golimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tocilizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Systemic Idiopathic Juvenile Arthritis - Dormant Projects
  • Systemic Idiopathic Juvenile Arthritis - Discontinued Products
  • Systemic Idiopathic Juvenile Arthritis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
      • Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
      • May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
      • Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
      • Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
      • Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics Inc, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H2 2017
  • Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top